A recent study analyzing patient reports found over 90% of UK pharmacists and doctors are dealing with ADHD medication shortages. Patients now face long drives to find prescriptions and experience severe withdrawal symptoms when their treatment is interrupted.
Key Takeaways
- A qualitative assessment of Reddit posts was published in Frontiers in Pharmacology in July 2025 examining the ADHD medication shortage in the United States
- Pharmacy supply shortages have resulted in patients often driving long distances to pick up their ADHD prescriptions, particularly impacting rural and underserved communities
- One patient with ADHD reported self-medicating with cannabis due to an ongoing shortage of methylphenidate
- More than 3.4 million children are currently prescribed ADHD medications in the United States
- Adult ADHD diagnoses rose annually from 2020 to 2023 according to the American Psychiatric Association
- The ADHD medication shortage is described as a public health crisis in the United States as of late 2025
- The DEA acknowledged as of late 2025 that the existing national inventory of Schedule II substances including d-amphetamine and methylphenidate is inadequate to meet legitimate patient needs
- The DEA increased Aggregate Production Quotas (APQs) for d-amphetamine and methylphenidate for 2025 in response to the shortage
- The UK Department of Health and Social Care issued a National Patient Safety Alert on 27 September 2023 regarding supply disruptions affecting various strengths of ADHD medication
- More than 9 in 10 pharmacists, GPs and prescribers reported ADHD medicines had been affected by shortages in a UK APPG survey
- 76% of pharmacists, GPs and prescribers said HRT and diabetes drugs had also been affected by shortages
- 44% of pharmacists, GPs and prescribers reported antibiotic shortages in addition to ADHD medication shortages
Across the US and UK, ADHD medication shortages force patients to travel, switch, or self medicate.
Related reading
01 · Category
Patient Impact & Experiences30 stats
01
A qualitative assessment of Reddit posts was published in Frontiers in Pharmacology in July 2025 examining the ADHD medication shortage in the United States
02
Pharmacy supply shortages have resulted in patients often driving long distances to pick up their ADHD prescriptions, particularly impacting rural and underserved communities
03
One patient with ADHD reported self-medicating with cannabis due to an ongoing shortage of methylphenidate
04
People with ADHD in West Yorkshire reported traveling journeys of up to one hour each way to obtain medication
05
Lacking ADHD medication as prescribed leads to patients experiencing detriments in managing their daily life and severe physical and mental withdrawal symptoms
06
Going without ADHD medication can significantly affect mood and ability to function in areas including work, relationships, socialising, and everyday tasks
07
The West Yorkshire ADHD Support Group reported through their Facebook page stories of people traveling significant distances to obtain ADHD medication
08
A Tufts University School of Medicine study published in July 2025 used Reddit posts as a data source to qualitatively assess the ADHD medication shortage in the US
09
Parents unable to access antibiotics for sick children and elderly patients facing delays in life-sustaining medication were cited alongside ADHD shortages in APPG report
10
The additional anxiety over ADHD medication shortage is described as a very significant extra burden on individuals already under significant daily stress due to the condition
11
ADHD medication shortage disproportionately impacts rural and underserved communities in the United States
12
Patients with ADHD face severe physical and mental withdrawal symptoms when they lack access to prescribed medication
13
Laura Shakesby aged 35 was diagnosed with ADHD in December 2022 and campaigns to raise awareness about the condition and medication shortages
14
Shortages are having significant impact on patients with conditions specifically including ADHD, menopause, and diabetes according to the UK APPG 2025 report
15
The US ADHD medication shortage has been analyzed using social media data including Reddit posts to understand patient experiences
16
People with ADHD are described as being under significant additional daily stress and organisational pressure by virtue of their condition making medication shortages especially burdensome
17
The UK ADHD shortage document includes patient counselling and signposting guidance for further information to support ADHD patients
18
The shortage of ADHD medications has caused patients to risk deterioration in all areas of life including work relationships socialising and everyday tasks
19
The shortage has created a situation where patients experiencing ADHD symptoms without medication have resorted to self-medication with unregulated substances
20
The West Yorkshire ADHD Support Group uses a Facebook page to document stories from people affected by the ADHD medication shortage
21
Patients in the UK facing ADHD medication shortages are dealing with the stress of an already challenging condition compounded by difficulties accessing treatment
22
The ADHD medication shortage has created anxiety for parents of children with ADHD who are already navigating significant organizational challenges of the condition
23
The UK ADHD shortage has led to increased reliance on specialist consultations before making changes to patients' ADHD prescriptions
24
The ADHD medication shortage is documented as causing significant harm to patients in a UK parliamentary investigation
25
The ADHD medication shortage has disproportionately affected patients in underserved areas who face additional barriers to accessing alternative pharmacies
26
ADHD medication shortages have impacted the health and wellbeing of both pediatric and adult patient populations in both the US and UK
27
The ADHD medication shortage in the US has led researchers to analyze patient experiences through unconventional data sources such as online forums and social media
28
The ADHD medication shortage in the UK has led to serious harm being reported by patients and healthcare professionals alike
29
The UK West Yorkshire ADHD Support Group provides support to individuals with diagnosed or suspected ADHD in the region and has documented medication shortage impacts
30
The ADHD medication shortage has been characterized as a crisis that impacts both the health system's capacity to treat patients and individual patient outcomes
Interpretation
Patient Impact & Experiences Interpretation
This critical shortage has transformed a routine prescription refill into a punishing scavenger hunt, compounding the daily struggles of ADHD with the acute distress of withdrawal and the profound risk of unmanaged symptoms, forcing patients to choose between driving for hours or facing collapse in their work, relationships, and mental health.
02 · Category
Prevalence & Diagnosis28 stats
01
More than 3.4 million children are currently prescribed ADHD medications in the United States
02
Adult ADHD diagnoses rose annually from 2020 to 2023 according to the American Psychiatric Association
03
The ADHD medication shortage is described as a public health crisis in the United States as of late 2025
04
Under-diagnosis of ADHD is described as especially acute in West Yorkshire where individuals are often misdiagnosed with anxiety, depression, learning difficulties, and personality disorders
05
The ADHD medication shortage study received by Frontiers in Pharmacology was received on November 16 2024 and accepted on June 6 2025
06
The ADHD medication shortage qualitative Reddit study was authored by researchers from Tufts University School of Medicine's Department of Public Health and Community Medicine
07
The ADHD medication shortage in the US is described as a public health crisis requiring strategic industry regulations and practices
08
The Frontiers in Pharmacology study on ADHD medication shortage was published on July 7 2025
09
The US ADHD medication shortage is driven in part by the great demand for first-line pharmacotherapy amid widespread shortages
10
The ADHD medication shortage in the US has led to a strained healthcare infrastructure due to rising adult ADHD diagnoses
11
The Tufts University ADHD medication shortage study was edited by Alvaro Francisco Lopes Sousa from Hospital Sirio Libanes Brazil
12
The ADHD medication shortage has impacted both children and adults who rely on stimulant medications as first-line treatment
13
ADHD is described by the NHS as a condition that makes it hard to concentrate and may cause people to act on impulse
14
The Tufts ADHD medication shortage study was co-authored by Shikhar Shrestha, Shama Varghese, Simran Mehta, and Saloni Dev from the Department of Public Health and Community Medicine
15
The US ADHD medication shortage involves widespread prescription treatment shortages that have been documented as a significant public health problem
16
The UK All-Party Parliamentary Group on pharmacy published its findings on medicine shortages in 2025 drawing on surveys of pharmacists, GPs, and prescribers
17
The UK ADHD medication shortage document covers both adult ADHD services and Child and Adolescent Mental Health services in its management guidance
18
The ADHD medication shortage is linked to increased global demand for ADHD treatments as more individuals are diagnosed worldwide
19
The rise in ADHD diagnoses among adults from 2020 to 2023 has added pressure to an already strained healthcare infrastructure dealing with medication shortages
20
The US ADHD medication shortage has been analyzed in peer-reviewed academic literature published by the National Library of Medicine
21
The ADHD medication shortage has been linked to rising rates of ADHD diagnosis in both the US and UK creating a demand that outpaces production capacity
22
The ADHD medication shortage is classified as a public health crisis with documented impacts on millions of patients in the United States
23
The ADHD medication shortage has been the subject of academic peer-reviewed research published in Frontiers in Pharmacology a leading international pharmacology journal
24
The global increase in ADHD diagnoses has been identified as a primary driver of the medication shortages experienced in both the US and UK
25
The ADHD medication shortage has generated significant public concern and media coverage reflecting the widespread impact on affected patients and families
26
The ADHD medication shortage has been documented in the scientific literature published in peer-reviewed international pharmacology journals indexing research available through PubMed Central
27
The ADHD medication shortage has led to documented societal concerns about the management of chronic conditions in both adult and pediatric populations
28
The ADHD medication shortage has been the subject of both parliamentary and academic scrutiny in 2025 reflecting its widespread recognition as a major public health concern
Interpretation
Prevalence & Diagnosis Interpretation
While a global surge in diagnoses has collided with a strained supply chain, leaving millions of adults and children in a desperate scramble for their essential medication, the real crisis is a healthcare system perpetually caught flat-footed by the predictable consequences of its own success in recognizing the condition.
More related reading
03 · Category
Regulatory & Policy Response30 stats
01
The DEA acknowledged as of late 2025 that the existing national inventory of Schedule II substances including d-amphetamine and methylphenidate is inadequate to meet legitimate patient needs
02
The DEA increased Aggregate Production Quotas (APQs) for d-amphetamine and methylphenidate for 2025 in response to the shortage
03
The UK Department of Health and Social Care issued a National Patient Safety Alert on 27 September 2023 regarding supply disruptions affecting various strengths of ADHD medication
04
The UK APPG on pharmacy called for urgent action to ensure medicine shortages do not become the new normal
05
Stimulant medications containing d-amphetamine and methylphenidate are classified as Schedule II substances under the Controlled Substances Act
06
Concerns about overmedication particularly in children and young adults have influenced ADHD medication regulatory practices
07
The APPG on pharmacy report noted that many MPs have received a growing volume of correspondence from constituents anxious about the availability of their medicines
08
The ADHD medication shortage in the US involves active ingredients d-amphetamine and methylphenidate which are both subject to DEA Aggregate Production Quotas
09
The DEA is responsible for enforcing regulations governing ADHD medication dispensing under the Controlled Substances Act (CSA)
10
The UK ADHD medication shortage memo was written to support healthcare professionals where patients have a diagnosis of ADHD and medications are unavailable
11
The ADHD medication shortage in the US is described as requiring a balance between proper access and production of pharmacotherapy while mitigating risks of substance abuse
12
The increased DEA APQs for 2025 allow manufacturers to increase production and pharmacies to increase inventory to better meet ADHD medication demand
13
The UK ADHD shortage document outlines suggested management options for healthcare professionals when specific ADHD medications are unavailable
14
The APPG report published in July 2025 recommended urgent government action to address the structural challenges of medicine shortages in the UK
15
The US federal government has expressed concern about overmedication for chronic conditions particularly in pediatric populations taking ADHD medications
16
The UK ADHD medication shortage memo includes general advice for specialist teams and services, primary care services, community pharmacies, and dispensing practices
17
The UK ADHD medication shortage memo notes that where medications affected are prescribed for an alternative indication the patient's specialist should be consulted before making changes
18
The APPG on pharmacy report was issued in 2025 after MPs received growing volumes of constituent correspondence about medicine availability
19
The UK ADHD shortage document includes contact details for Adult ADHD Services and Child and Adolescent Mental Health services to assist healthcare professionals
20
The All-Party Parliamentary Group on pharmacy highlighted ADHD medication shortages as one of the most critical areas affecting patient safety in the UK in 2025
21
The US ADHD medication shortage involves concerns about substance abuse risks associated with stimulant medications classified as Schedule II substances
22
The UK ADHD medication shortage has led to the development of specific guidance for community pharmacies and dispensing practices on managing supply issues
23
The US ADHD medication shortage has prompted discussion about the balance between DEA regulatory constraints and patient access to necessary medications
24
The ADHD medication shortage in the US is analyzed within the context of the Controlled Substances Act which governs production quotas and dispensing of stimulant medications
25
The DEA's Aggregate Production Quota system is identified as a key regulatory mechanism limiting the supply of ADHD medications in the US
26
The ADHD medication shortage is described as necessitating strategic industry regulations and practices to ensure appropriate access to pharmacotherapy
27
The UK ADHD medication shortage is described as a national patient safety concern requiring coordinated response across the healthcare system
28
The ADHD medication shortage has prompted calls for greater resilience in the medicines supply chain underpinning NHS care
29
The ADHD medication shortage in the US was the subject of a November 2025 law review article examining DEA regulations and limitations in addressing the crisis
30
The DEA regulatory framework governing ADHD medication production is described as having significant limitations in addressing the current public health crisis
Interpretation
Regulatory & Policy Response Interpretation
This crisis, where patients are frantically hunting for their vital ADHD medication while regulators nervously eye the quota sheets, perfectly captures the absurdly fine line between treating a disorder and fearing we might create another.
04 · Category
Supply Chain & Shortage Scope30 stats
01
More than 9 in 10 pharmacists, GPs and prescribers reported ADHD medicines had been affected by shortages in a UK APPG survey
02
76% of pharmacists, GPs and prescribers said HRT and diabetes drugs had also been affected by shortages
03
44% of pharmacists, GPs and prescribers reported antibiotic shortages in addition to ADHD medication shortages
04
The UK ADHD medication shortage memo was originally issued on 09 October 2023 and updated as recently as 16 June 2025, indicating the shortage has persisted for nearly two years
05
Seven different types of ADHD drugs were reported to be affected by the UK shortage according to the DHSC
06
The UK ADHD medication shortages are attributed to a combination of manufacturing issues and increased global demand
07
Medications affected in the UK shortage include methylphenidate prolonged-release capsules and tablets, lisdexamfetamine capsules, and guanfacine prolonged-release tablets
08
ADHD medication shortages have become increasingly severe, persistent, and disruptive in recent years according to a UK APPG report
09
Medicine shortages are having significant consequences for patients, staff, and the wider UK health service according to the APPG report in 2025
10
The UK ADHD medication shortage memo covers Guanfacine prolonged release (Intuniv), Lisdexamfetamine prolonged release (Elvanse), Methylphenidate modified release tablets (Concerta XL, Xaggitin XL, Xenidate XL), and Atomoxetine capsules and oral solution
11
Frontline pharmacy teams cannot safely expand clinical services while daily supply disruptions continue to impact patient health according to the APPG report
12
The DHSC UK shortage alert stated supply issues for ADHD drugs could last until the end of 2023
13
The UK ADHD medication shortage memo noted it is unknown when supply issues will be resolved as of its latest update in June 2025
14
Pharmacy is described as central to NHS recovery and transformation yet is undermined by supply disruptions according to the APPG 2025 report
15
Medicine shortages have moved from isolated incidents to a chronic structural challenge for both the NHS and pharmacy sector according to the APPG 2025 report
16
The ADHD medication shortage in the UK involves supply disruptions affecting various strengths of the medications licensed for ADHD treatment
17
The UK ADHD shortage includes disruptions to Concerta XL, Xaggitin XL and Xenidate XL tablet preparations of methylphenidate modified release
18
Campaigners raised concerns in November 2023 about a national shortage of ADHD medication in the UK affecting seven different drug types
19
The ongoing ADHD medication shortage has resulted in pharmacists being overwhelmed by the need to source alternative medications
20
Atomoxetine capsules and oral solution are among the ADHD medications affected by the UK shortage
21
Lisdexamfetamine prolonged release sold as Elvanse is one of the ADHD medications affected by the UK shortage
22
Guanfacine prolonged release sold as Intuniv is one of the ADHD medications affected by the UK shortage
23
The UK APPG report noted that medicine shortages are not a new phenomenon but have become increasingly severe and persistent in recent years
24
The UK medicine shortage has made it difficult for pharmacists to expand clinical roles due to ongoing supply disruptions
25
The UK APPG report identified ADHD medication alongside menopause and diabetes drugs as the most severely impacted medicine categories in the ongoing shortage
26
The UK shortage of ADHD medications has impacted supply information for adult ADHD services and Child and Adolescent Mental Health services
27
The medicine shortage situation in the UK has been characterized as a chronic structural challenge rather than isolated incidents
28
The ADHD medication shortage is recognized as a global issue with both the US and UK experiencing simultaneous shortages of similar medications
29
The UK ADHD shortage document notes the shortage situation was initially anticipated to be resolved by end of 2023 but persisted well beyond that timeframe
30
ADHD medications including methylphenidate and amphetamine salts are first-line pharmacotherapy treatments that are now experiencing widespread global shortages
Interpretation
Supply Chain & Shortage Scope Interpretation
The statistics paint a starkly predictable picture: a perfect storm of manufacturing hiccups and soaring demand has led to a nearly two-year, system-wide scramble for ADHD medications, proving that when the global supply chain for controlled substances gets a headache, it’s the patients, pharmacists, and doctors who are left desperately searching for the aspirin.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Margot Villeneuve. (2026, February 24). ADHD Medication Shortage Statistics. Gitnux. https://gitnux.org/adhd-medication-shortage-statistics
MLA
Margot Villeneuve. "ADHD Medication Shortage Statistics." Gitnux, 24 Feb 2026, https://gitnux.org/adhd-medication-shortage-statistics.
Chicago
Margot Villeneuve. 2026. "ADHD Medication Shortage Statistics." Gitnux. https://gitnux.org/adhd-medication-shortage-statistics.
Sources & references
5 datasets cited across this report · attribution is report-level